Inhibition of cyclin-dependent kinase 7 mitigates doxorubicin cardiotoxicity and enhances anticancer efficacy
Cardiovascular Research · 2024
DOI: 10.1093/cvr/cvae084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, 2024. Verfasst von Jingrui Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Washington State University, 412 E. Spokane Falls Blvd., Spokane, WA 99202-2131, USA. Hauptthemen laut MEDLINE: Doxorubicin, Myocytes, Cardiac, Cardiotoxicity, Cyclin-Dependent Kinases. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NIH.
Abstract (Originalsprache)
Aims
The anthracycline family of anticancer agents such as doxorubicin (DOX) can induce apoptotic death of cardiomyocytes and cause cardiotoxicity. We previously reported that DOX-induced apoptosis is accompanied by cardiomyocyte cell cycle re-entry. Cell cycle progression requires cyclin-dependent kinase 7 (CDK7)-mediated activation of downstream cell cycle CDKs. This study aims to determine whether CDK7 can be targeted for cardioprotection during anthracycline chemotherapy. Methods and results DOX exposure induced CDK7 activation in mouse heart and isolated cardiomyocytes. Cardiac-specific ablation of Cdk7 attenuated DOX-induced cardiac dysfunction and fibrosis. Treatment with the covalent CDK7 inhibitor THZ1 also protected against DOX-induced cardiomyopathy and apoptosis. DOX treatment induced activation of the proapoptotic CDK2–FOXO1–Bim axis in a CDK7-dependent manner. In response to DOX, endogenous CDK7 directly bound and phosphorylated CDK2 at Thr160 in cardiomyocytes, leading to full CDK2 kinase activation. Importantly, inhibition of CDK7 further suppressed tumour growth when used in combination with DOX in an immunocompetent mouse model of breast cancer.
Conclusion
Activation of CDK7 is necessary for DOX-induced cardiomyocyte apoptosis and cardiomyopathy. Our findings uncover a novel proapoptotic role for CDK7 in cardiomyocytes. Moreover, this study suggests that inhibition of CDK7 attenuates DOX-induced cardiotoxicity but augments the anticancer efficacy of DOX. Therefore, combined administration of CDK7 inhibitor and DOX may exhibit diminished cardiotoxicity but superior anticancer activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Washington State University, 412 E. Spokane Falls Blvd., Spokane, WA 99202-2131, USA.
ORCID-Profile: Zhaokang Cheng
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- NIH
- WSU College of Pharmacy and Pharmaceutical Sciences
- National Heart, Lung, and Blood Institute
- National Cancer Institute
Zitieren
APA
Chen, J., Wei, J., Xia, P., Liu, Y., Belew, M. D., Toohill, R., Wu, B. J., & Cheng, Z. (2024). Inhibition of cyclin-dependent kinase 7 mitigates doxorubicin cardiotoxicity and enhances anticancer efficacy. Cardiovascular Research. https://doi.org/10.1093/cvr/cvae084
Vancouver
Chen J, Wei J, Xia P, Liu Y, Belew MD, Toohill R, et al. Inhibition of cyclin-dependent kinase 7 mitigates doxorubicin cardiotoxicity and enhances anticancer efficacy. Cardiovascular Research. 2024. doi:10.1093/cvr/cvae084
BibTeX
@article{Chen2024,
author = {Chen, Jingrui and Wei, Jing and Xia, Peng and Liu, Yuening and Belew, Mahder Dawit and Toohill, Ryan and Wu, Boyang Jason and Cheng, Zhaokang},
title = {Inhibition of cyclin-dependent kinase 7 mitigates doxorubicin cardiotoxicity and enhances anticancer efficacy},
journal = {Cardiovascular Research},
year = {2024},
doi = {10.1093/cvr/cvae084}
}
EUVIMED